The company has seen its share price slump and reputation tarnished despite its best efforts to help tackle Covid
Thursday 08 Apr 2021 Author: Tom Sieber
Global multi-national businesses with billions of pounds in revenue and profit aren’t obvious candidates for sympathy but it’s hard not to feel a bit sorry for AstraZeneca ( AZN ) after its experience over the last six months. In partnership with Oxford University, AstraZeneca has developed a Covid jab in record time which can be easily stored and transported and, unlike other vaccine developers, agreed initially to produce it...